Ï㽶ֱ²¥

Treatments that make the optic nerve resilient to elevated eye pressure and ageing are severely lacking. Existing treatments can lower eye pressure but don’t protect the optic nerve, only slowing vision loss. Neuroprotective treatments could prevent vision loss and reduce the need for surgery or medications. 

Our program will collaborate with leading national and international research groups across four research platforms:

• µþ¾±´Ç±ô´Ç²µ²â:ÌýConducts pre-clinical research into the impact of advancing age, mitochondrial and metabolic dysfunction on optic nerve resilience to glaucoma.
• Pathway Discovery: Integrates data from multiomic cell and tissue analysis to identify novel pathways that inform new therapeutic targets for protecting the optic nerve in glaucoma.
• Translation Accelerator: Designs, optimises and translates candidate small molecules and RNA therapies into clinical trial-ready assets.
• °ä±ô¾±²Ô¾±³¦²¹±ô:ÌýDevelop designs for faster and more affordable clinical trials and establish a major patient cohort (recruit 1000 glaucoma patients) to guide biomarker development and have a ready pool of well-characterised patients to speed up clinical trial recruitment.

Over the next 10 years we aim to develop new therapies that increase optic nerve resilience to eye pressure elevation.